Role of vascular endothelial growth factor receptor in the pro-proliferation activity of CD40-CD40L in AGS gastric cancer cells

Asian Biomedicine

Volumn 4, Issue 5, 2010, Pages 797-802

  Ning, Yongling ^a   Qian, Keqing ^a   Qi, Chunjian ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

CD40; Gastric cancer; sCD40L; VEGF; VEGFR

Indexed keywords

EID: 84871696852     PISSN: 19057415     EISSN: 1875855X     Source Type: Journal    
DOI: 10.2478/abm-2010-0104     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58:71-96. (Pubitemid 351521864)
2. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008; 122:2286-93. (Pubitemid 351542333)
3. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008; 266:99-115.
4. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22:307-328. (Pubitemid 38680425)
5. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007; 13:1083-8. (Pubitemid 46424046)
6. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001; 58:4-43. (Pubitemid 32143961)
7. Ochs HD, Hollenbaugh D, Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin Immunol. 1994; 6:337-41. (Pubitemid 124001531)
8. Qi CJ, Zheng L, Ma HB, Fei M, Qian KQ, Shen BR, Wu CP, Vihinen M, Zhang XG. A novel mutation in CD40 and its functional characterization. Hum Mutat. 2009; 30:985-94.
9. Murugaiyan G, Martin S, Saha B. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. 2007; 28:467-73. (Pubitemid 350103683)
10. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC, Zuzel M, Chen H. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005; 19:524-30. (Pubitemid 40521154)
11. Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother 2000;49:101-108. (Pubitemid 30431646)
12. Li R, Chen WC, Wang WP, Tian WY, Zhang XG. CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells. Immunol Lett. 2010; 131:120-5.
13. Kim SW, Lee HS, Yoon SK, Chung WC, Cho YS, Jeong JJ, et al. Expression of CD40 in gastric cancer and its effect on the apoptosis of gastric cancer cells. Korean J Gastroenterol. 2003; 42:274-82.
14. Tomeczkowski J, Beilken A, Frick D, Wieland B, Konig A, Falk MH, et al. Absence of c-kit receptor and absent proliferative response to stem cell factor in childhood Burkitt's lymphoma cells. Blood. 1995; 86:1469-80.
15. Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, Wang H, et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science. 2008; 321:663-8.
16. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007; 19:2487-97. (Pubitemid 47531929)
17. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem. 2003; 278:18008-14. (Pubitemid 36799410)
18. Shafee N, Kaluz S, Ru N, Stanbridge EJ. PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett. 2009; 282:109-15.
19. Edelmann J, Klein-Hitpass L, Carpinteiro A, Fuhrer A, Sellmann L, Stilgenbauer S, et al. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res. 2008; 32:1565-72.
20. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008; 68:6598-607.
21. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene. 2008; 27:3999-4007. (Pubitemid 351913633)
22. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA. 2008; 105:9739-44. (Pubitemid 352031370)
23. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, et al. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol. 2008; 181:8088-95.
24. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004; 103:3883-9. (Pubitemid 38596309)